BioXcel Therapeutics (BTAI) Misses Q1 EPS by 17c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($0.87), $0.17 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $582 thousand versus the consensus estimate of $440 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Middleby board approves spin-off of food processing unit Midera
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance